A Multicenter Study To Determine Foscarnet Dose Response in HIV Infected Patients With PGL and/or Constitutional Disease
Status:
Completed
Trial end date:
1992-06-01
Target enrollment:
Participant gender:
Summary
To determine the toxicity of low dose foscarnet administered for 4 weeks to HIV infected
patients who are asymptomatic, have AIDS, or other HIV associated conditions and a CD4+
lymphocyte count < 500 cells/mm3. To obtain preliminary efficacy data. Although zidovudine
(AZT) has been effective in treating some AIDS patients, AZT has toxic effects in many
patients and other means of treating HIV-infected persons need to be evaluated. In vitro
(test tube) studies have shown that the human herpes viruses are inhibited by foscarnet and
that a number of retroviruses, including HIV, are sensitive to it. It is hoped that treatment
of HIV-infected individuals with foscarnet during an early phase of HIV infections will
reduce the risk of developing AIDS.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)